Jump to content
Powered by

GENOVAC starts a project to develop blocking antibodies for the therapy of hepatitis C infections

GENOVAC GmbH has started a research project funded by the German Ministry for Business and Technology (BMWi), as part of the program PRO INNO II, for the "Development and validation of antibodies as a novel therapeutic concept to block liver infection by hepatitis C Virus".

According to Dr Fritz Grunert (CSO) the joint developmental project with the French partner INSERM U748, Strasbourg, aims to design, develop and pre-clinically validate the basics for a novel therapeutic approach in the prevention and treatment of hepatitis C (HCV) infections.

The development of monoclonal antibodies that block epitopes of known cellular HCV receptors will be the focus of this project. Following a comprehensive characterisation, more functional-therapeutic research using in vitro liver cell models are planned. „We would like to develop a platform for a completely novel therapeutic concept in the treatment of HCV infections. A renowned scientific partner in this field, Prof. Thomas Baumert, Director of the Institute of Virology at the INSERM U748 will help us to achieve this goal“, said Dr John Thompson, Managing Director of GENOVAC GmbH. “On completion, we then plan to test the antibodies in vivo in pre-clinical studies”.

First results from Prof. Baumert’s group look extremely promising and will be presented at the upcoming “15th International Symposium on hepatitis C virus and related viruses“ in San Antonio, Texas, USA from 5th -9th of October 2008.

„After a consistent and successful expansion of our service portfolio during the last couple of years, we are now aiming to support our business model with own product developments. Our technology has the potential and together with the right partners, we shall successfully translate this into business“, summarises Dr Stefan Lang, Director Business Development at GENOVAC GmbH.

GENOVAC GmbH

The GENOVAC GmbH started in 1999 as a spin-off from the University of Freiburg, Germany. During the current fiscal year a revenue of 1.8 Mill. EUR and an anticipated profit (before tax) of 400,000 EUR is forecasted. 14 employees work at the headquarters in Freiburg.

GENOVAC has established itself as a world leader in the area of antibody generation by genetic immunisation. Innovative proprietary technologies allow the production and identification of highly specific antibodies influencing function directly through immunisation with a cDNA.

GENOVAC offers solutions to help scientists at critical phases of their work. GENOVAC is a customer-oriented service provider who, through intensive interaction helps to guide and advise its clients, in order to find optimal solutions to their individual needs. GENOVAC has an impressive list of more than 500 international customers and cooperation partners. This list includes renowned national and international research centres as well many global players in the pharmaceutical, biotechnology and agricultural sectors, where GENOVAC is often listed as a preferred vendor.

Source: Press release GENOVAC GmbH - 18.09.2008 (P)
For further information contact:
GENOVAC GmbH
Dr. Stefan Lang
Waltershofener Str. 17
79111 Freiburg
Deutschland
Tel.: +49-(0)761-45636-0
Fax: +49-(0)761-45636-29
E-Mail: info@genovac.com
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/genovac-starts-a-project-to-develop-blocking-antibodies-for-the-therapy-of-hepatitis-c-infections